Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Provided in the methods section, Line 133-233 and Table 1	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	Provided in the methods section, paragraph named "Cell lines and cell culture", line 134-135	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		Not used

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		Not used
Animal observed in or captured from the field: Provide species, sex and age where possible		Not used
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		Not used

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		Not used
Microbes: provide species and strain, unique accession number if available, and source		Not used

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Provided in the methods section, paragraph named "Patients specimen and clinical data", line 129-131	
Provide statement confirming informed consent obtained from study participants.	Provided in the methods section, paragraph named "Patients specimen and clinical data", line 131	
Report on age and sex for all study participants.	Provided in the methods section, paragraph named "Patients specimen and clinical data", line 120-121	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		Not clinical trials

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		Not available

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination		Not carried out
Randomisation		Not carried out
Blinding		Not carried out
Inclusion/exclusion criteria	Provided in the methods section, paragraph named "Patients specimen and clinical data", line 117-119	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Provided in the methods section, paragraph named "Statistical analysis", line 262	
Define whether data describe technical or biological replicates		Not provided

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Provided in the methods section, paragraph named "Patients specimen and clinical data", line 129-131	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		Not used
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Provided in the methods section, paragraph named "Patients specimen and clinical data", line 129-131	

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		No dual use

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		Not stated

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Provided in the methods section, paragraph named "Statistical analysis", line 264-271	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Provided in the methods section, paragraph named "Transcriptome sequencing and functional enrichment analysis", line 257-259	
If data are publicly available, provide accession number in repository or DOI or URL.	Provided in the methods section, paragraph named "Transcriptome sequencing and function enrichment analysis", line 257-259	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Provided in the methods section, paragraph named "Data downloading and Bioinformatics analysis", line 237-239	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		No newly generated code
If code is publicly available, provide accession number in repository, or DOI or URL.		No newly generated code

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/atm-20-3731